We are live on ! Find out more
ECYT

Endocyte, Inc. Common Stock
ECYT

Delisted

ECYT was delisted on the 20th of December, 2018.

Back to rankings

90 hedge funds and large institutions have $48M invested in Endocyte, Inc. Common Stock in 2016 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 25 increasing their positions, 31 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

554% more call options, than puts

Call options by funds: $353K | Put options by funds: $54K

3% less capital invested

Capital invested by funds: $49.4M → $48M (-$1.42M)

6% less funds holding

Funds holding: 96 → 90 (-6)

19% less repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 31

56% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 9

Holders
90
Holders Change
-6
Holders Change %
-6.25%
% of All Funds
2.39%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
25
Reduced
31
Closed
9
Calls
$353K
Puts
$54K
Net Calls
+$299K
Net Calls Change
+$83K

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$589K
2
HCMT
Highland Capital Management (Texas)
Texas
+$545K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$489K
4
BFA
BlackRock Fund Advisors
California
+$427K
5
Deutsche Bank
Deutsche Bank
Germany
+$341K

Top Sellers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
-$815K
2
Millennium Management
Millennium Management
New York
-$479K
3
JP Morgan Chase
JP Morgan Chase
New York
-$190K
4
EGA
Eagle Global Advisors
Texas
-$168K
5
OAM
Oxford Asset Management
United Kingdom
-$140K

ECYT Hedge Fund Activity: Q3 2016 in Review

90 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Endocyte, Inc. Common Stock (ECYT) for Q3 2016, worth a combined $48M — down 2.9% from $49.4M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of ECYT and 4 opened new positions — a net loss of 5 holders — while 31 trimmed existing stakes and 25 added.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $589K. The largest seller was Baker Bros. Advisors, cutting an estimated $815K.

  • 90 institutional investors held Endocyte, Inc. Common Stock (ECYT) as of Q3 2016, down from 96 in Q2 2016.
  • Funds reported $48M of Endocyte, Inc. Common Stock stock for Q3 2016, down 2.9% quarter-over-quarter.
  • 4 funds opened new Endocyte, Inc. Common Stock positions in Q3 2016 and 9 closed out, a net change of -5 holders.
  • The largest Endocyte, Inc. Common Stock buyer in Q3 2016 was Renaissance Technologies, an estimated $589K added.
  • The largest Endocyte, Inc. Common Stock seller in Q3 2016 was Baker Bros. Advisors, an estimated $815K sold.

Based on aggregated 13F filings for Q3 2016.